Journal article
Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer
World journal of clinical oncology, Vol.6(5), pp.156-165
10/10/2015
DOI: 10.5306/wjco.v6.i5.156
PMCID: PMC4600190
PMID: 26468452
Abstract
AIM: To prospectively determine the safety and tolerability of oral L-selenomethionine (SLM) with concurrent chemoradiation (CCRT) for Stage III non-small cell lung cancer (NSCLC) and estimate if the incidence and/or severity of adverse events could be reduced by its use.
METHODS: Sixteen patients with stage III NSCLC were accrued to this single arm, phase II study. CCRT consisted of radiation given at 2 Gy per fraction for 30-33 fractions, 5 d per week with concurrent weekly. paclitaxel 50 mg/m(2) followed by carboplatin dosed at an area under the time-concentration curve of 2. SLM was dosed in a loading phase at 4800 mu g twice daily for one week prior to CCRT followed by once daily dosing during treatment.
RESULTS: No selenium-related toxicity was observed. Analysis revealed grade 3 or higher esophagitis in 3 of 16 patients (19%), pneumonitis in 0, leukopenia in 2 (12.5%), and anemia in 1 (6%); the latter two were significantly reduced when compared to the protocol-stated expected rate of 35% (P = 0.045 for leukopenia, and P < 0.01 for anemia). Median overall survival was 14.9 mo and median failure-free survival was 9 mo (95% CI: 3.3-21.5).
CONCLUSION: There may be some protective benefit of selenium in the setting of CCRT for inoperable NSCLC. The data suggests decreased rates of myelosuppression when compared to similarly-treated historical and contemporary controls. Further evaluation of selenium in this setting may be warranted.
Details
- Title: Subtitle
- Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer
- Creators
- Michael Mix - Roswell Park Cancer InstituteNithya Ramnath - Roswell Park Cancer InstituteJorge Gomez - Roswell Park Cancer InstituteCharles de Groot - Roswell Park Cancer InstituteSaju Rajan - Roswell Park Cancer InstituteShiva Dibaj - Roswell Park Cancer InstituteWei Tan - Roswell Park Cancer InstituteYoucef Rustum - Roswell Park Cancer InstituteMichael B. Jameson - Roswell Park Cancer InstituteAnurag K. Singh - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- World journal of clinical oncology, Vol.6(5), pp.156-165
- DOI
- 10.5306/wjco.v6.i5.156
- PMID
- 26468452
- PMCID
- PMC4600190
- NLM abbreviation
- World J Clin Oncol
- ISSN
- 2218-4333
- eISSN
- 2218-4333
- Publisher
- Baishideng Publishing Group Inc
- Number of pages
- 10
- Grant note
- P30CA016056 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) Health Research Council of New Zealand
- Language
- English
- Date published
- 10/10/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359947002771
Metrics
12 Record Views